Spero Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $8.6M | $-68.6M | $22.8M | $-46.4M | $-89.8M | $-78.3M | $-60.9M | $-41.7M |
| Depreciation & Amortization | $0 | $2.0K | $367.0K | $869.0K | $646.0K | $761.0K | $750.0K | $409.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $4.3M | $7.8M | $7.9M | $9.1M | $9.4M | $4.9M | $3.8M | $2.7M |
| Net Cash from Operating Activities | $-12.6M | $-23.4M | $-33.0M | $-7.7M | $-64.3M | $-85.9M | $-50.0M | $-39.6M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | $157.0K | $314.0K | $2.4M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | $0 | $33.8M | $7.7M | $10.5M | $29.5M | $-83.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $0 | $221.0K | $-29.6M | $84.1M | $130.9M | $16.1M | $69.5M |
| Net Change in Cash | $-12.6M | $-23.4M | $-32.8M | $-3.5M | $27.4M | $55.5M | $-4.4M | $-53.3M |
| Free Cash Flow | — | — | — | — | — | $-86.0M | $-50.3M | $-42.1M |